A phase 1, first-in-human study of Guselkumab (an IL-23-specific mAb) to demonstrate clinical and molecular response in patients with moderate-to-severe psoriasis.

Trial Profile

A phase 1, first-in-human study of Guselkumab (an IL-23-specific mAb) to demonstrate clinical and molecular response in patients with moderate-to-severe psoriasis.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Apr 2014 New trial record
    • 01 Apr 2014 Results published in the Journal of Allergy and Clinical Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top